This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The CCC score was excellent for 82% of the children in the propofol-succinylcholine group and for 55% of those in the sevoflurane group, (p<0.05). The score was good for 18% of the children in the propofol-succinylcholine group and for 45% of those in the sevoflurane group.
The data from the questionnaires (obtained from 48 of the 64 children) showed no significant difference in terms of the incidence of nausea, vomiting or pain between the groups.
Fifteen children (75%) in the propofol-succinylcholine group found induction pleasant, compared with 12 children (43%) in the sevoflurane group.
Twelve children (69%) in the propofol-succinylcholine group stated that they would have the same anaesthetic again, compared with 13 children (46%) in the sevoflurane group. However, this difference did not achieve statistical significance.
Clinical conclusions
The effectiveness analysis showed that both anaesthetics were generally equally effective for tracheal intubation, although the scores were slightly better for the propofol-succinylcholine group than for the sevoflurane group.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. A cost-consequences analysis was therefore carried out.
Direct costs
Discounting was irrelevant due to the short time horizon of the study. The unit costs and the quantities of resources used were reported separately. The items included in the cost analysis were the drug costs. The cost/resource boundary adopted was that of the NHS. The costs were estimated using actual drug acquisition costs, while the quantities of resources were obtained from the trial. No dates were reported and no price year was given.
